Current therapies and progress in the treatment of advanced gastric cancer

Abstract

Gastric cancer (GC) remains one of the most life-threatening disease worldwide with poor prognosis because of the absence of effective treatment and the delay in diagnosis. Due to the delay of diagnosis, a large proportion of GC patients are diagnosed as advanced GC, with extreme short lifespan. In the past few years, some pivotal progress and novel therapies was proposed, and conducted into clinical researches and practice. In this study, we summarized the development of several novel immunotherapy or targeted treatment modalities for advanced GC, including immune checkpoint inhibitors, anti-angiogenic therapy and cancer vaccines. Additionally, the advantage and potential weakness in each of these therapeutic methods are also listed. Finally, we discussed the promising research direction of advanced GC treatment, and the limitation in basic and clinical research of advanced GC, including the combination of immunotherapy and targeted therapy.

Prognosis and Treatment of Gastric Cancer: A 2024 Update

“…Because there is currently no effective treatment for GC and detection is often delayed, GC is still one of the most serious diseases in the world and has a poor prognosis. Many GC patients are classified as having advanced GC, with extremely short lifespans, as a result of delayed diagnosis [5]. Treatment plans for GC now include a strong emphasis on multidisciplinary team consultation.…”

Prognostic Influence of Galectin-1 in Gastric Adenocarcinoma

“…Indeed, limited progress has been made in targeted therapies following the discovery of the aforementioned treatments. However, the development of anti-claudin therapies has opened a horizon of hope for advanced GC patients, and numerous ongoing trials are exploring novel and promising targets such as FGFR and MET, new antiangiogenic, immunotherapeutic, and anti-HER2 approaches, as well as innovative drug delivery systems [8][9][10][11][12].…”